Treatment Information


Ovarian Cancer treatment details. Biologic therapy.

National Cancer Institute, Bethesda, Maryland, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Bethesda, Maryland
Treatments:Biologic therapyHospital:National Cancer Institute
Date:Apr 2007


Patients: This phase II study involved 24 women with recurrent epithelial ovarian cancer with a median age of 53, ranging from 33-67. Of these, 16 completed the treatment and were evaluated by the researchers.

Treatment: These women were treated with gefitinib (Iressa), a small molecule that inhibits the epidermal growth factor receptor.

Toxicity: Grade 4 toxicities were experienced by two women: one had hyponatremia and another hemorrhaged due to her spleen rupturing. Grade 3 toxicities were abdominal pain, diarrhea, and an abnormal lab result. Grade 2 toxicities included anorexia, diarrhea, nausea, vomiting, fatigue, weight loss, and skin changes.

Results: There were no complete or partial responses. Nine patients had stable disease for more than two months. Median survival times were not reported.

Correspondence: Elise C. Kohn, M.D.